Indirect comparison of nivolumab ± ipilimumab (CheckMate 032) versus other treatments for recurrent small-cell lung cancer-Reference-Cited by-同舟云学术

Indirect comparison of nivolumab ± ipilimumab (CheckMate 032) versus other treatments for recurrent small-cell lung cancer

Published:2019-07 Issue:10 Volume:8 Page:733-751
ISSN:2042-6305
Container-title:Journal of Comparative Effectiveness Research
language:en
Short-container-title:Journal of Comparative Effectiveness Research

Author:

Cope Shannon¹,Keeping Sam T¹,Goldgrub Rachel¹,Ayers Dieter¹,Jansen Jeroen P²,Penrod John R³,Korytowsky Beata³,Juarez-Garcia Ariadna⁴,Yuan Yong³

Affiliation:

1. Precision Xtract, Vancouver, BC, V6H 3Y4, Canada

2. Precision Xtract, Oakland, CA 94612, USA

3. Bristol-Myers Squibb, Princeton Pike, Lawrence Township, NJ 08648, USA

4. Bristol-Myers Squibb, Uxbridge, Middlesex, UB8 1DH, UK

Abstract

Aim: To estimate the comparative efficacy of nivolumab ± ipilimumab versus alternative treatments for small-cell lung cancer after at least one prior line of chemotherapy. Materials & m ethods: A systematic literature review identified six randomized controlled trials (RCTs) that could be connected in a network. The Kaplan–Meier survival curves from these RCTs were synthesized using network meta-analysis models. Aggregate-level matching was used to connect CheckMate 032 to the RCTs. Results: CheckMate 032 was connected to the network by Amrubicin Clinical Trial-1. Nivolumab ± ipilimumab had a more durable tumor response and more favorable long-term survival versus topotecan via intravenous and versus amrubicin. Conclusion: Compared with chemotherapies for recurrent small-cell lung cancer, nivolumab ± ipilimumab improves response duration, which may translate to long-term survival benefits.

Publisher

Future Medicine Ltd

Subject

Health Policy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/cer-2018-0130

Reference65 articles.

1. Small cell lung cancer: Where do we go from here?

2. Small-cell lung cancer

3. Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

4. Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline

5. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer—what limits limited disease?

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New avenues for the treatment of immunotherapy-resistant pancreatic cancer;World Journal of Gastrointestinal Oncology;2024-04-15

2. Unanchored Population-Adjusted Indirect Comparison Methods for Time-to-Event Outcomes Using Inverse Odds Weighting, Regression Adjustment, and Doubly Robust Methods With Either Individual Patient or Aggregate Data;Value in Health;2023-12

3. Small Cell Lung Carcinoma;Diagnostic Imaging of Lung Cancers;2023

4. Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments;Cancers;2021-06-08

5. Comparative effectiveness of nivolumab versus standard of care for third-line patients with small-cell lung cancer;Journal of Comparative Effectiveness Research;2020-12